Skip to main content
SpringerLink
Log in

Lower 25-Hydroxyvitamin D is Associated with Higher Relapse Risk in Patients with Relapsing-Remitting Multiple Sclerosis

  • Published:
The journal of nutrition, health & aging

Abstract

Objectives

To investigate the association between serum circulating 25-hydroxyvitamin D [25(OH) D] concentrations and exacerbation risk in Chinese patients with relapsing-remitting multiple sclerosis (RR-MS).

Methods

From January 2014 to December 2014, consecutive RR-MS patients admitted to the Department of Neurology of our hospital were identified. Blood samples for 25(OH) D measurements were taken at admission. All included patients visited the outpatient clinic of our hospital 1 year after admission. The influence of serum 25[OH] D levels on exacerbation was performed by binary logistic regression analysis.

Results

In this study, 109 patients finished the follow-up. Median follow-up time was 1 year (range 1.0–1.1). Twenty-one out of the 109 was at risk period for infection. A total of 32 patients experienced a total of 76 exacerbations during the study. In the follow-up, a total of 32 patients experienced exacerbations. Thus, the exacerbation rate was 29.4% (95%CI: 20.8%-37.9%). Exacerbation rates were found to decrease with increasing levels of serum 25-OH-D concentrations. For the quartiles category, the risk of an exacerbation was significantly increased in the group with first quartile compared to the group with fourth. Rate ratios for the first, second and third group were 4.2, 3.3 and 2.0, respectively (p for trend =0.011) when compared with the fourth group. Simultaneous evaluation of quartile categories of levels of serum 25(OH) D and infections showed that both factors were related to the exacerbation rate.

Conclusion

The data demonstrates that lower vitamin D status is a sign of more active disease in patients with RR-MS and suggests a beneficial effect of vitamin D on disease course in MS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table 1
Table 2
Figure 1
Figure 2
Table 3

Similar content being viewed by others

References

  1. Lucchinetti, C., Bruck, W., Parisi, J., Scheithauer, B., Rodriguez, M., Lassmann,H. Heterogeneity of multiple sclerosis lesions: implicationsfor the pathogenesis of demyelination. Ann Neurol 2000;47:707–717.

    Article  CAS  PubMed  Google Scholar 

  2. Frota E R C, Rodrigues D H, Donadi E A, et al. Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse. Neuroscience letters 2009;460(2):130–132.

    Article  CAS  PubMed  Google Scholar 

  3. Gold R, Wolinsky J S, Amato M P, et al. Evolving expectations around early management of multiple sclerosis. Therapeutic advances in neurological disorders 2010;3(6):351–367.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502–1517.

    Article  CAS  PubMed  Google Scholar 

  5. Munger KL, Zhang SM, O’Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004;62(1):60–65.

    Article  CAS  PubMed  Google Scholar 

  6. Martinelli V, Dalla Costa G, Colombo B, et al. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler 2014;20(2):147–155.

    Article  CAS  PubMed  Google Scholar 

  7. Banwell B, Bar-Or A, Arnold DL, et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol 2011;10(5):436–445.

    Article  CAS  PubMed  Google Scholar 

  8. Ueda P, Rafatnia F, Bäärnhielm M, et al. Neonatal vitamin D status and risk of multiple sclerosis. Annals of neurology 2014;76(3):338–346.

    Article  CAS  PubMed  Google Scholar 

  9. Salzer J, Hallmans G, Nyström M, et al. Vitamin D as a protective factor in multiple sclerosis. Neurology, 2012, 79(21):2140–2145.

    Article  CAS  PubMed  Google Scholar 

  10. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum25-hydroxyvitamin D levels and risk of multiplesclerosis. JAMA 2006;296:2832–2838.

    Article  CAS  PubMed  Google Scholar 

  11. Løken-Amsrud KI, Holmøy T, Bakke SJ, et al. Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment. Neurology 2012;79(3):267–273.

    Article  PubMed  Google Scholar 

  12. Mowry E M, Waubant E, McCulloch C E, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Annals of neurology 2012;72(2):234–240.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Pandit L, Ramagopalan S V, Malli C, et al. Association of vitamin D and multiple sclerosis in India. Multiple Sclerosis Journal 2013;19(12):1592–1596.

    Article  PubMed  Google Scholar 

  14. Ascherio A, Munger K L, White R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA neurology 2014;71(3):306–314.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Simpson S Jr, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010;68:193–203.

    CAS  PubMed  Google Scholar 

  16. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–127.

    Article  CAS  PubMed  Google Scholar 

  17. Kurtzke JF. Rating neurologic impairment in multiplesclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–1452.

    Article  CAS  PubMed  Google Scholar 

  18. Buljevac D, Flach HZ, Hop WC, et al. Prospective studyon the relationship between infections and multiple sclerosisexacerbations. Brain 2002;125:952–960.

    Article  CAS  PubMed  Google Scholar 

  19. Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965;122:552–568.

    Article  CAS  PubMed  Google Scholar 

  20. Runia, T., Hop, W., de Rijke, Y., Buljevac, D. and Hintzen, R. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 2012;79:261–266.

    Article  CAS  PubMed  Google Scholar 

  21. Brola WP, Sobolewski W, Szczuchniak A, et al. Association of seasonal serum 25-hydroxyvitamin D levels with disability and relapses in relapsing-remitting multiple sclerosis. Eur J Clin Nutr 2016;70(9):995–999.

    Article  CAS  PubMed  Google Scholar 

  22. Smolders, J., Menheere, P., Kessels, A., Damoiseaux, J. and Hupperts, R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008;14:1–5.

    Article  Google Scholar 

  23. Pierrot-Deseilligny C, Souberbielle J C. Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis. Therapeutic advances in neurological disorders 2013;6(2):81–116.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Mowry, E., Krupp, L., Milazzo, M., Chabas, D., Strober, J., Belman, A. et al. Vitamin D status is associated with relapse rate in pediatric-onset MS. Ann Neurol 2010;67:618–624.

    CAS  PubMed  Google Scholar 

  25. Pierrot-Deseilligny C, Rivaud-Péchoux S, Clerson P, et al. Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Therapeutic advances in neurological disorders 2012;5(4):187–198.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Kampman, M., Steffensen, L., Mellgren, S. and Jørgensen, L. Effect of vitamin D3 supplementation on relapses, disease progression and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler 2012;18:1144–1151.

    Article  PubMed  Google Scholar 

  27. Soilu-Hänninen, M., Aivo, J., Lindström, B., Elovaara, I., Sumelhati, M., Färkkilä, M. et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an addon treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:565–571.

    Article  PubMed  Google Scholar 

  28. Mokry L E, Ross S, Ahmad O S, et al. Vitamin D and risk of multiple sclerosis: a Mendelian randomization study. PLoS Med, 2015, 12(8):e1001866.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Smolders J, Schuurman K G, van Strien M E, et al. Expression of Vitamin D Receptor and Metabolizing Enzymes in Multiple Sclerosis—Affected Brain Tissue. Journal of Neuropathology & Experimental Neurology, 2013, 72(2):91–105.

    Article  CAS  Google Scholar 

  30. Cantorna, M., Zhao, J. and Zhang, L. Vitamin D, invariant natural killer T-cells and experimental autoimmune disease. Proc Nutr Soc 2012;71:62–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Hewison, M. An update on vitamin D and human immunity. Clin Endocrinol 2012;76:315–325.

    Article  CAS  Google Scholar 

  32. Mahon, B., Gordon, S., Cruz, J., Cosman, F. and Cantorna, M. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol 2003;134:128–132

    Article  CAS  PubMed  Google Scholar 

  33. Smolders J, Thewissen M, Peelen E, et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PloS one 2009;4:e6635

    Article  Google Scholar 

  34. Bobryshev YV. Vitamin D3 suppresses immune reactions in atherosclerosis, affecting regulatory T cells and dendritic cell function. Arterioscler Thromb Vasc Biol 2010;30:2317–2319.

    Article  CAS  PubMed  Google Scholar 

  35. Smolders J, Peelen E, Thewissen M, et al. Circulating vitamin D binding protein levels are not associated with relapses or with vitamin D status in multiple sclerosis. Multiple Sclerosis Journal, 2014,20(4):433–437.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong University, NO.324, Jingwu Road, Huaiyin district, Jinan, 250021, P. R. China

    C. Wang, Z. Zeng, B. Wang & Shougang Guo

Authors
  1. C. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shougang Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shougang Guo.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, C., Zeng, Z., Wang, B. et al. Lower 25-Hydroxyvitamin D is Associated with Higher Relapse Risk in Patients with Relapsing-Remitting Multiple Sclerosis. J Nutr Health Aging 22, 38–43 (2018). https://doi.org/10.1007/s12603-017-0894-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12603-017-0894-3

Key words

Search

Navigation